看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。2 ?3 p* K/ e8 m2 y& b* N6 ], m
# \. @) U! n( D6 J& }0 s( p# U+ B7 t5 N4 ^
Currently available feasibility data for possible combination strategies.
6 R/ w1 ]7 Z& \- `$ G( `% u————————————————————————————————' L# H" `/ g0 {% Q6 W
Combination Feasibility according to preliminary data
4 T% @% n5 p& q3 x——————————————————————————————————
! e A7 S3 q, b7 Z0 g' R. x+ nBevacizumab + sorafenib Yes, reduced dose
' ~( p( z3 W% OBevacizumab + sunitinib† No
! u8 K S* a, Z3 m/ QBevacizumab + temsirolimus Yes ) P7 U/ C+ f$ Z) V
Bevacizumab + everolimus Yes # R4 v: |3 L2 u4 z
Sorafenib + sunitinib ? 8 A4 C, q: S; Q2 g) \3 H
Sorafenib + temsirolimus Yes, reduced dose
% y4 d3 L4 u+ c$ l2 l8 k- b7 r5 @Sorafenib + everolimus Yes, reduced dose 3 }9 g# M( N1 U4 F4 o, P
Sunitinib + temsirolimus† No
+ ?9 \) `( B$ c7 ~9 w9 d/ mSunitinib + everolimus ? : u( ^ n9 l- H: o5 }+ a+ U9 ^* r
Temsirolimus + everolimus ? 3 a& b4 c: G% ^& x& e' _
————————————————————
! [& h) T$ F; d†Led to US FDA warning.0 L1 j: R J$ W& `6 I( J
?: As yet unattempted combination. z. v( i7 V5 W4 H2 q! D \' y
|
显身卡
# O5 f: C8 v4 A/ e+ Y
